| General Information | |
|---|---|
| ZINC ID | ZINC000028648895 |
| Molecular Weight (Da) | 426 |
| SMILES | O=C(NC1CCCCC1)c1cnc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)n1 |
| Molecular Formula | C23Cl2N3O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.001 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 6.246 |
| Activity (Ki) in nM | 16.5959 |
| Polar Surface Area (PSA) | 54.88 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.13 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.26 |
| Ilogp | 4.33 |
| Xlogp3 | 5.96 |
| Wlogp | 6.18 |
| Mlogp | 3.71 |
| Silicos-it log p | 5.99 |
| Consensus log p | 5.24 |
| Esol log s | -6.37 |
| Esol solubility (mg/ml) | 0.000183 |
| Esol solubility (mol/l) | 0.00000042 |
| Esol class | Poorly sol |
| Ali log s | -6.89 |
| Ali solubility (mg/ml) | 0.0000551 |
| Ali solubility (mol/l) | 0.00000012 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.25 |
| Silicos-it solubility (mg/ml) | 0.00000023 |
| Silicos-it solubility (mol/l) | 5.58E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.67 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.09 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.15 |
| Logd | 4.789 |
| Logp | 6.243 |
| F (20%) | 0.043 |
| F (30%) | 0.898 |
| Mdck | - |
| Ppb | 99.20% |
| Vdss | 3.003 |
| Fu | 0.74% |
| Cyp1a2-inh | 0.603 |
| Cyp1a2-sub | 0.171 |
| Cyp2c19-inh | 0.757 |
| Cyp2c19-sub | 0.063 |
| Cl | 4.123 |
| T12 | 0.019 |
| H-ht | 0.849 |
| Dili | 0.974 |
| Roa | 0.756 |
| Fdamdd | 0.66 |
| Skinsen | 0.045 |
| Ec | 0.003 |
| Ei | 0.018 |
| Respiratory | 0.286 |
| Bcf | 2.395 |
| Igc50 | 5.058 |
| Lc50 | 6.012 |
| Lc50dm | 5.819 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.229 |
| Nr-ahr | 0.463 |
| Nr-aromatase | 0.88 |
| Nr-er | 0.571 |
| Nr-er-lbd | 0.04 |
| Nr-ppar-gamma | 0.941 |
| Sr-are | 0.902 |
| Sr-atad5 | 0.761 |
| Sr-hse | 0.836 |
| Sr-mmp | 0.925 |
| Sr-p53 | 0.973 |
| Vol | 417.976 |
| Dense | 1.017 |
| Flex | 0.2 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.542 |
| Synth | 2.136 |
| Fsp3 | 0.261 |
| Mce-18 | 50.69 |
| Natural product-likeness | -0.982 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |